Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence

• Asıl Yazarlar: Celia Posada (Yazar), Ángeles Flórez (Yazar), Ana Batalla (Yazar), Juan José Alcázar (Yazar), Daniel Carpio (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Karger Publishers, 2011-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Adalimumab is a fully human monoclonal anti-tumor necrosis factor-α agent that is approved for the treatment of Crohn's disease. It has a good safety profile, injection site reactions being the most common adverse effect. We report a case of a 54-year-old woman with a 30-year history of Crohn&#...